Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate

Bone

Volumn 39, Issue 4, 2006, Pages 872-879

  Allen, Matthew R ^a   Iwata, Ken ^a   Phipps, Roger ^d   Burr, David B ^a,b,c  

^a Department of Anatomy and Cell Biology ^*  (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Indiana University Purdue University Indianapolis   (United States)

^d PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Bisphosphonate; Histomorphometry; Osteoporosis; Remodeling

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DENSITY; BONE MINERALIZATION; BONE TURNOVER; CONTROLLED STUDY; DOG; DOSE RESPONSE; FEMALE; GEOMETRY; HISTOLOGY; NONHUMAN; POSTMENOPAUSE OSTEOPOROSIS; STATISTICAL SIGNIFICANCE; TRABECULAR BONE; TREATMENT DURATION; VERTEBRA;

ALENDRONATE; ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ETIDRONIC ACID; FEMALE; LUMBAR VERTEBRAE; TIME FACTORS;

EID: 33748175899     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.04.028     Document Type: Article

References (34)

1. Delmas P.D. How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?. Bone 27 (2000) 1-3
2. Dufresne T., Chmielewski P., Manhart M., Johnson T., and Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73 (2003) 423-432
3. Rodan G.A., and Fleisch H.A. Bisphosphonates: mechanisms of action. J Clin Invest 97 (1996) 2692-2696
4. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687-694
5. Currey J.D., Brear K., and Zioupos P. The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech 29 (1996) 257-260
6. Currey J.D. Tensile yield in compact bone is determined by strain, post-yield behaviour by mineral content. J Biomech 37 (2004) 549-556
7. Les C.M., Stover S.M., Keyak J.H., Taylor K.T., and Kaneps A.J. Stiff and strong compressive properties are associated with brittle post-yield behavior in equine compact bone material. J Orthop Res 20 (2002) 607-614
8. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
9. Komatsubara S., Mori S., Mashiba T., Ito M., Li J., Kaji Y., et al. Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18 (2003) 512-520
10. Bone H.G., Hosking D., Devogelaer J.-P., Tucci J.R., Emkey R.D., Tonino R.P., et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350 (2004) 1189-1199
11. Delmas P.D., and Seeman E. Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34 (2004) 599-604
12. Seeman E. The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am 32 (2003) 25-38
13. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., and Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100 (1997) 1475-1480
14. Burr D.B., and Stafford T. Validity of the bulk-staining technique to separate artifactual from in vivo bone microdamage. Clin Orthop Relat Res (1990) 305-308
15. Martin B., Fyhrie D.P., and Yeh O.C. Sampling bones for microcracks. Trans Orthop Res Soc 30 (2005) [Abstract 1540]
16. Parfitt A., Drezner M., Glorieux F., Kanis J., Malluche H., Meunier P., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2 (1987) 595-610
17. Huja S.S., Hasan M.S., Pidaparti R., Turner C.H., Garetto L.P., and Burr D.B. Development of a fluorescent light technique for evaluating microdamage in bone subjected to fatigue loading. J Biomech 32 (1999) 1243-1249
18. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 (2000) 613-620
19. Norman T.L., and Wang Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 20 (1997) 375-379
20. O'Brien F.J., Taylor D., and Clive Lee T. The effect of bone microstructure on the initiation and growth of microcracks. J Orthop Res 23 (2005) 475-480
21. Rosen C.J., Hochberg M.C., Bonnick S.L., McClung M., Miller P., Broy S., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20 (2005) 141-151
22. Sebba A.I., Bonnick S.L., Kagan R., Thompson D.E., Skalky C.S., Chen E., et al. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. Curr Med Res Opin 20 (2004) 2031-2041
23. Burr D. Microdamage and bone strength. Osteoporos Int 14 Suppl 5 (2003) 67-72
24. Li J., Sato M., Jerome C., Turner C.H., Fan Z., and Burr D.B. Microdamage accumulation in the monkey vertebra does not occur when bone turnover is suppressed by 50% or less with estrogen or raloxifene. J Bone Miner Metab 23 (2005) 48-54 [Suppl]
25. Burr D.B., Martin R.B., Schaffler M.B., and Radin E.L. Bone remodeling in response to in vivo fatigue microdamage. J Biomech 18 (1985) 189-200
26. Martin R.B. Is all cortical bone remodeling initiated by microdamage?. Bone 30 (2002) 8-13
27. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
28. Delmas P.D., Li Z., and Cooper C. Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19 (2004) 330-337
29. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
30. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
31. Komatsubara S., Mori S., Mashiba T., Li J., Nonaka K., Kaji Y., et al. Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage but maintains intrinsic material properties in cortical bone of dog rib. J Bone Miner Res 19 (2004) 999-1005
32. Christiansen C., Phipps R., Burgio D., Sun L., Russell D., Keck B., et al. Comparison of risedronate and alendronate pharmacokinetics at clinical doses. Osteoporos Int 14 (2003) S38
33. Nancollas G.H., Tang R., Phipps R.J., Henneman Z., Gulde S., Wu W., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38 (2006) 617-627
34. Shen V., Dempster D.W., Birchman R., Mellish R.W., Church E., Kohn D., et al. Lack of changes in histomorphometric, bone mass, and biochemical parameters in ovariohysterectomized dogs. Bone 13 (1992) 311-316